Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Capital Expenditures (2017)

vTv Therapeutics (VTVT) has disclosed Capital Expenditures for 3 consecutive years, with $18000.0 as the latest value for Q4 2017.

  • Quarterly Capital Expenditures changed N/A to $18000.0 in Q4 2017 from the year-ago period, while the trailing twelve-month figure was $18000.0 through Dec 2021, changed N/A year-over-year, with the annual reading at $21000.0 for FY2022, N/A changed from the prior year.
  • Capital Expenditures hit $18000.0 in Q4 2017 for vTv Therapeutics, down from $39000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $62000.0 in Q4 2015 to a low of -$2000.0 in Q4 2014.
  • Historically, Capital Expenditures has averaged $21000.0 across 3 years, with a median of $13500.0 in 2014.
  • Biggest YoY gain for Capital Expenditures was 3200.0% in 2015; the steepest drop was 0.0% in 2015.
  • Year by year, Capital Expenditures stood at -$2000.0 in 2014, then soared by 3200.0% to $62000.0 in 2015, then tumbled by 70.97% to $18000.0 in 2017.
  • Business Quant data shows Capital Expenditures for VTVT at $18000.0 in Q4 2017, $39000.0 in Q1 2017, and $62000.0 in Q4 2015.